Do not use in patients with hypersensitivity to midostaurin or its excipients. Hypersensitivity reactions have included anaphylactic shock, dyspnea, flushing, chest pain, and angioed…
If you prescribe RYDAPT for newly diagnosed FLT3+ AML based on the approved label, and there is a delay in your patients’ insurance coverage as they transition out of the hospital, they may be eligible to receive a free 14-day supply of RYDAPT shipped directly to their home to avoid disruption in their treatment.
No purchase of RYDAPT is required. Novartis cannot guarantee that every patient who enrolls in RYDAPT NOW will be successful in obtaining insurance coverage for treatment or will receive financial assistance.
To learn more about this support program and patient eligibility, or to enroll your patient, please call 1-800-282-7630.
*Limitations apply. This offer is only available to patients with private insurance. The program is not available for patients that are enrolled in Medicare, Medicaid, or any other federal or state health care program. Novartis reserves the right to rescind, revoke, or amend this program without notice. For full Terms and Conditions, visit CoPay.NovartisOncology.com or call 1-877-577-7756.
Encourage your patients to find out if they are eligible to enroll in the Universal Co-pay Program by visiting CoPay.NovartisOncology.com or calling 1-877-577-7756.
Acute Myeloid Leukemia
RYDAPT is indicated, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation–positive, as detected by an FDA-approved test.
Limitations of Use
RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML.
Please see full Prescribing Information for RYDAPT® (midostaurin) capsules.